BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The HER2 space continues to storm ahead of other oncology fiel
 ds due to the overwhelming success of Enhertu and the continued satisfact
 ion with Herceptin. As we enter 2023\, the field shows no sign of slowing
  down and it is turning its attention to non-breast cancer types where An
 ti-HER2 therapeutics are already making massive strides. It’s not just AD
 Cs either like the aforementioned successes\; multispecific antibodies\, 
 cell therapy\, and radiopharmaceuticals are bringing strong results for p
 atients with various cancer types at various clinical stages. Demonstrati
 ng that there are many stones still unturned and plenty of opportunity st
 ill out there for developers with HER2 in mind.\n\nThis is the one-stop-s
 hop for all challenges HER2. Tackle the challenges at the heart of treati
 ng HER2-expressing breast cancer and non-breast tumors. Overcome the deve
 lopment challenges to advance therapeutics of all varieties quickly throu
 gh your pipeline\, ADCs\, immunotherapies\, and radiopharmaceuticals alik
 e.\n\nAccompanying you from preclinical through to post-approval indicati
 on agnostic trials\, this meeting has been designed to enable the field t
 o expand the clinical utility of HER2 as a multi-tumor target with a mult
 iple modality approach and an aspiration to push beyond the boundaries of
  breast cancer.\n
DTEND:20231101T180000
DTSTAMP:20260512T232941Z
DTSTART:20231030T080000
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, Massachuset
 ts\, 02128\,
SEQUENCE:0
SUMMARY:The HER2 space continues to storm ahead of other oncology fields d
 ue to the overwhelming success of Enhertu and the continued satisfaction 
 with Her...
UID:f195a848-81b2-41cf-873d-088e8e9e4299
END:VEVENT
END:VCALENDAR